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Tuberculosis (TB) has become a worldwide threat, mainly due to the emergence of
multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium
tuberculosis (Mtb). This mini-review is focused on the various mechanisms of resistance
to the currently available anti-TB drugs and provides perspective on novel strategies and
lead scaffolds/compounds aimed at inhibiting/overcoming these resistance mechanisms.
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INTRODUCTION
Approximately 1.4 million deaths were attributed to Mtb infec-
tions in 2012. When compared to other infectious agents, only
HIV claims more lives (WHO, 2012). While recent efforts have
resulted in a global decline in TB incidence and mortality (WHO,
2011), the number of individuals infected with drug-resistant
isolates continues to increase, presenting a serious global health
threat. Generally, drug-susceptibleMtb infections are treated with
a combination of four compounds; rifampicin (RIF), ethambutol
(EMB), pyrazinamide (PZA), and isoniazid (INH) for 2 months,
followed by treatment with RIF and INH for 4 additional months
(Lienhardt et al., 2012) (Figure 1A). By definition, MDR-TB is
resistant to the most potent first-line drugs, RIF and INH. The
WHO reports that ∼60,000 cases of MDR-TB were diagnosed
in 2011, likely an underestimate. To treat MDR-TB, second-
line drugs including fluoroquinolones (FQs), amikacin (AMK),
kanamycin (KAN), and capreomycin (CAP) are employed. These
drugs are administered for ∼20 months and can be toxic, poorly
tolerated, and difficult to procure. Approximately 95% of MDR-
TB is XDR-TB, having additional resistance to at least one FQ
and one injectable drug (AMK, KAN, or CAP), and for which
treatment options are limited. Therefore, new therapeutics are
critically needed to overcome drug resistance and to eliminate TB
as a public health threat.
Herein we briefly discuss the drugs currently used to treat TB
and the respective mechanisms of resistance followed by a review
of approaches aimed toward overcoming TB drug resistance.
CURRENT DRUGS AND RESISTANCE
Mtb is intrinsically resistant to many antibiotics due to the low
permeability of its mycolic acid-rich waxy cell envelope, the
action of efflux pumps (Banerjee et al., 1996; Silva et al., 2001;
Singh et al., 2011), and the presence of chromosomally encoded
resistance genes. Drug resistance inMtb has been emerging due to
the accumulation of chromosomal mutations and not acquisition
of mobile genetic elements. The major mechanisms of acquired
drug resistance inMtb can be broken down into several categories:
(1) mutations or modifications (e.g., RNA methylation) of the
drug targets (RIF, EMB, KAN, AMK, CAP, and the FQs), (2) the
inability to activate a prodrug [INH, PZA, ethionamide (ETH)]
due to mutations leading to a loss of function, and (3) enzymatic
inactivation of the drug (KAN).
MUTATIONS ORMODIFICATIONS OF THE DRUG TARGETS
Mutations
Antibiotics target cellular processes that are vital in bacteria by
binding their targets at a specific site, often directly interacting
with key functional residues of the target. The most common
mechanism of resistance in Mtb is the alteration of the target’s
binding site through the accumulation of mutations. These muta-
tions decrease the binding affinity of the drug to its target and
typically occur in a very defined region of the gene termed the
resistance-determining region. This mechanism is used by Mtb to
confer resistance to RIF, EMB, and FQs by altering the binding
site of their respective targets: the β-subunit of RNA polymerase
(Campbell et al., 2001), a glycosyltransferase (Telenti et al., 1997),
and DNA gyrase (Takiff et al., 1994). Similarly, ribosomal muta-
tions (e.g., A1401G) in the 16S rRNA have been found to confer
resistance to AMK, KAN, and CAP (Wachino et al., 2010).
Modifications
An alternative mode of resistance in Mtb is the inactivation of
rRNA methyltransferase enzymes. Mutations in TlyA hinder-
ing the methylation activity of rRNA 2′-O-methyltransferase at
nucleotides C1409 of 16S rRNA and C1920 of 23S rRNA have
been linked to resistance to the ribosome-targeting drugs CAP
and viomycin (VIO) (Johansen et al., 2006). Mutations in a puta-
tive 16S rRNA methyltransferase, GidB, were found to confer
low-level resistance to the aminoglycoside (AG) streptomycin
(STR) (Spies et al., 2011; Wong et al., 2011).
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FIGURE 1 | (A) Structures of the anti-TB drugs discussed in this mini-review. (B) Schematic representation of the three methodologies explored to overcome
resistance in Mtb.
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INABILITY TO ACTIVATE A PRODRUG
Three first-line drugs, INH, PZA, and ETH, are prodrugs that
must be metabolized to be active against Mtb. INH is activated
by the catalase-peroxidase, KatG, and produces isonicotinic-
acyl radicals that react with NADH to form an INH-NADH
adduct. The adduct binds its main target, enoyl-acyl carrier
protein reductase (InhA), and inhibits mycolic acid biosynthe-
sis. ETH is a structural analog of INH and is activated by the
monooxygenase EthA, which oxidizes ETH to its active form,
2-ethyl-4-amidopyridine. This activated compound also targets
InhA and blocks mycolic acid biosynthesis similarly to INH. PZA
is activated by pyrazinamidase/nicotinamidase, PncA, to pyrazi-
noic acid (POA). The proposed targets of POA range from cell
membrane energy to fatty acid synthesis, but the exact killing
mechanism of POA remains unclear. Resistance to any of the
prodrugs can arise due to reduced metabolism by their corre-
sponding activator. Structural mutations that lower or abolish
the enzymatic activity of KatG (Ramaswamy et al., 2003; Hazbon
et al., 2006), EthA (Baulard et al., 2000; Debarber et al., 2000;
Morlock et al., 2003), and PncA (Stoffels et al., 2012; Rajendran
and Sethumadhavan, 2013) were found to lead to INH, ETH, and
PZA resistance, respectively. Mutations in InhA causing overex-
pression of the target (Baulard et al., 2000; Debarber et al., 2000;
Larsen et al., 2002) or preventing binding of the active form of
INH and ETH to the target (Banerjee et al., 1994; Vilcheze et al.,
2008) also confer cross-resistance to these drugs.
INACTIVATION OF THE DRUG
Drugmodification is perhaps themost prevalent and well-studied
resistance mechanism employed by bacteria. Many bacteria either
degrade or modify the offending compound thereby generating
an inactive molecule. Resistance to penicillin is mediated by a
class of enzymes known as the β-lactamases, which inactivate
the antibiotic by destroying the β-lactam ring. Mtb naturally
harbors a chromosomally encoded class A β-lactamase, BlaC,
which is constitutively expressed providing intrinsic resistance to
penicillin (Hugonnet and Blanchard, 2007). One mechanism of
acquired resistance to AGs, such as KAN and AMK, is their mod-
ification and inactivation by a family of enzymes known as AG-
modifying enzymes (AMEs) (Ramirez and Tolmasky, 2010; Labby
and Garneau-Tsodikova, 2013). Mtb expresses two AMEs, the AG
2′-N-acetyltransferace AAC(2′)-Ic (Hegde et al., 2001) and the
enhanced intracellular survival (Eis) protein (Zaunbrecher et al.,
2009). Both enzymes acetylate AGs, reducing the ability of these
drugs to inhibit the ribosome. In the case of Eis, increased expres-
sion due to mutations in the eis promoter or the 5′-untranslated
region of the transcriptional activator WhiB7 leads to clinically
relevant, low-level resistance to KAN (Zaunbrecher et al., 2009;
Reeves et al., 2013). A unique feature of Eis resides in its ability
to modify AGs at multiple sites in vitro, completely inactivating
these compounds (Chen et al., 2011). A recent report has shown
that Eis also acetylates CAP at its β-lysine side chain in vitro, but
the clinical relevance of this finding remains unclear (Houghton
et al., 2013).
METHODOLOGIES TO OVERCOME RESISTANCE
Three major strategies have been explored to overcome resis-
tance in TB: (1) identification of novel drugs for well-established
targets, (2) identification and characterization of novel com-
pounds that target unexplored vital cell processes or enzymes,
thus killing the cell by preventing regular metabolism, and (3)
identification of compounds that behave synergistically with cur-
rent anti-TB drugs (Figure 1B).
DISCOVERY OF NOVEL DRUGS FOR KNOWN TARGETS
DNA gyrase
Among the known Mtb drug targets, DNA gyrase remains attrac-
tive for development of inhibitors interacting with either GyrA
or GyrB subunits. To overcome the FQ resistance of DNA gyrase
mutants, a series of 30 ofloxacin derivatives with various sub-
stituents ortho to the fluoro moiety of the FQ scaffold were
synthesized (Dinakaran et al., 2008). These compounds dis-
played MIC99 values <10μM and retained anti-mycobacterial
activity against MDR-Mtb strains.While ofloxacin displayed a 17-
fold lower activity against MDR-Mtb relative to susceptible Mtb
strains, its derivatives displayed at most a 4-fold lower activity
and, in some cases, higher activity against MDR-Mtb. The tox-
icity of selected compounds in mammalian Vero cells displayed
a range of IC50 values (60 to >150μM), 6-fold higher than the
highest MIC99 value. When tested in culture, the compound with
the best MIC99 value showed reduction inMtb colonies similar to
that observed with ofloxacin.
While many efforts have been directed toward the develop-
ment of FQ analogs to target the GyrA subunit of DNA gyrase,
development of inhibitors targeting GyrB has also been pursued.
A series of aminopyrazinamides were found to target the ATPase
site of GyrB and inhibit the growth of Mtb in the low micro-
molar/high nanomolar range (Shirude et al., 2013). A variety
of naphthoquinones were also discovered to inhibit the ATPase
domain of the GyrB subunit of Mtb DNA gyrase with IC50 val-
ues between 15 and >200μM (Karkare et al., 2013). The most
promising naphthoquinone, diospyrin, was tested against DNA
gyrase from other bacterial species and found to be a broad
spectrum DNA gyrase inhibitor. The aminobenzimidazole AB-
1 was also investigated for its inhibitory properties of GyrB and
compared to the well-characterized GyrB inhibitor novobiocin
(Chopra et al., 2012). AB-1 displayed lower MIC values than
novobiocin with Mtb strains resistant to STR, INH, CIP, and
p-aminosalicylic acid. AB-1 also displayed improved activity in
aerobic and anaerobic conditions while not interfering with RIF
or INH mechanisms.
KatG/InhA inhibition
To overcome mutations of KatG and other mechanisms of INH
resistance, analogs of INH have been synthesized. Early genera-
tions of INH analogs incorporated aryloxyacetonitriles onto the
hydrazide of the INH scaffold (Bukowski et al., 1999). These com-
pounds were then evolved into 1,2,3-triazole derivatives withMIC
values slightly higher than those of INH (Boechat et al., 2011).
As an alternative strategy to overcoming KatG mutations or
deletion, InhA inhibitors, not needing KatG activation, have
been investigated. Triclosan (Parikh et al., 2000) served as a lead
compound for the design of a series of 5-alkyl-diphenyl ethers
(Sullivan et al., 2006). These ethers displayed IC50 values for
InhA ranging from 5 nM to 2μM, displayed higher bactericidal
activity than the parent triclosan, and were further optimized to
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slow the release time from the InhA active site (Luckner et al.,
2010). More recently, from screening 300 molecules, CD117 was
identified as an InhA inhibitor that likely targets other enzymes
(Vilcheze et al., 2011). CD117 was active against hypoxic Mtb
and yielded 80% Vero cell viability at the highest concentration
tested. This year, virtual screening efforts led to the identifi-
cation of 7 potential InhA inhibitors (Kinjo et al., 2013). In
model Mycobacterium species the top hit compounds displayed
similar growth inhibition to that of INH and directly inhibited
Mtb InhA.
Cell membrane construction
The inhibition of cell membrane construction also remains a tar-
get of choice for the development of new drugs. Nitroimidazoles
such as PA-824 and OPC-67683 have been found to inhibit
the synthesis of membrane proteins and lipids (Mukherjee and
Boshoff, 2011). Much like INH and PZA, PA-824 is a prodrug
that requires activation by reduction of its nitro group (Stover
et al., 2000). PA-824 and OPC-67683 have demonstrated activity
against both susceptible and resistant-Mtb strains (Stover et al.,
2000; Rivers and Mancera, 2008a,b). PA-824 showed activity in
the high ng/mL range for both susceptible and resistant-Mtb
(Ginsberg et al., 2009) and OPC-67683 displayed better MIC
values in the low ng/mL range (Matsumoto et al., 2006).
Benzothiazinones (BTZs) (Makarov et al., 2006), such
as BTZ043, have also been shown to interfere with cell
membrane construction. Like EMB, these compounds disrupt
arabinan’s biosynthesis by targeting decaprenylphosphoryl-β-D-
ribose 2′-epimerase (DprE) (Makarov et al., 2009). In infected
macrophages, BTZ043 showed a faster decrease in percentage of
infected cells and bacterial load compared to INH or RIF. BTZ043
has also been tested in 240 clinical isolates of Mtb from European
hospitals and was active against all strains (Pasca et al., 2010).
DISCOVERY OF NOVEL DRUGS FOR NEW TARGETS
ATP homeostasis
One of the challenges in treating TB is the organism’s extended
period(s) of dormancy.One key difference in the states of growing
and hypoxic non-growing Mtb is a reduced, but significant, ATP
pool in the non-growing organism (Rao et al., 2008). A plausible
way to attack the non-growing bacilli is to affect their ATP storage
by inactivating ATP synthase to deplete the ATP and eventually
kill the bacilli (Andries et al., 2005). This strategy led to the iden-
tification of the ATP synthase inhibitor TMC207 (bedaquiline or
sirturo), which was approved by the FDA in December 2012 for
TB treatment (Diacon et al., 2009; Avorn, 2013). TMC207 is the
first FDA-approved anti-TB drug in 40 years (Mahajan, 2013).
TMC207 targets the C-subunit of ATP synthase proton pump
and mutations are known that are resistant to this novel com-
pound (Segala et al., 2012). There are also some mycobacterial
strains that are naturally resistant to TMC207. Because of the
potential risks associated with this drug, it is recommended that
it be utilized only in patients for which other treatment options
have failed. A high-throughput screen (HTS) to identify addi-
tional compounds that block ATP synthesis and kill dormantMtb
resulted in 0.5% hit rate from a library of 600,000 compounds
(Mak et al., 2012).
Pantothenate synthetase
Pantothenate synthetase has also been explored as an antibi-
otic target of Mtb. Actinomycin D was identified via HTS as an
inhibitor of this de novo synthesis enzyme (Yang et al., 2011).
Futher in silico HTS led to the discovery of two compounds
that inhibit the panthothenate synthesis 10× more efficiently
than actinomycin D does. These compounds displayed identical
MIC values against susceptible and MDR-Mtb strains. Analogs
of the pantothenate synthetase reaction intermediate were shown
to bind the enzyme more tightly than the nucleotide substrate
(Ciulli et al., 2008). Another essential enzyme, pantothenate
kinase (CoaA) has also been considered as a target. Three classes
of compounds were found to target CoaA: triazoles, quinoline
carboxamides, and biaryl acetic acids (Venkatraman et al., 2012).
All compounds inhibited CoaA with IC50 values ranging from
70 nM to 8.4μMwith various modes of inhibition.
Dehydroquinase of the shikimate pathway
The essential shikimate pathway, responsible for the biosynthe-
sis of aromatic amino acids, folate, and vitamins E/K, is also
an antibacterial target (Gonzalez-Bello and Castedo, 2007; Payne
et al., 2007a,b; Tran et al., 2011). Recently, inhibitors of the
dehydroquinase enzyme of the shikimate pathway have been opti-
mized againstMtb and a series of 3,4-dihydroxyacetophenone and
acetonide cores with MIC values in the low-micromolar range
were identified (Tran et al., 2012). Similarly, a series of anhy-
droquinones were synthesized and found to be low-micromolar
to high-nanomolar Mtb dehydroquinase inhibitors (Payne et al.,
2007a; Prazeres et al., 2007). Other studies have focused on gener-
ating dehydroquinic acid derivatives (Lence et al., 2013) or 3-alkyl
enol mimics (Blanco et al., 2012) to inhibit dehydroquinase
and disrupt the shikimate pathway. Dehydroquinic acid analogs
showed IC50 values in the mid-nanomolar range (26–100 nM),
while the 3-alkyl enol mimics had a broader nanomolar range
(28–780 nM).
MmpL3 (TMM transporter)
SQ109 is an EMB analog with an adamantyl moiety that tar-
gets cell well-biosynthesis. SQ109 was discovered in a screen
of ∼63,000 compounds and showed high ng/mL MIC values
(Sacksteder et al., 2012). Recent studies revealed that SQ109 acts
on MmpL3, the trehalose monomycolate (TMM) transporter
of Mtb (Tahlan et al., 2012). Adamantyl ureas, discovered by
high-throughput screening, also displayed anti-tubercular activ-
ity (Brown et al., 2011) by targeting MmpL3 (Grzegorzewicz
et al., 2012). Since their discovery, the structure of organic ureas
has undergone several optimizations for solubility (Scherman
et al., 2012) and pharmacokinetic properties (North et al., 2013).
Additional scaffolds based on the structure of the pyrrole deriva-
tive BM212 have also recently emerged as MmpL3 inhibitors
(Poce et al., 2013).
SYNERGISTIC DRUG COMBINATION
Combination of unrelated drugs
In an effort to reduce emerging resistance, combinations of small
molecules have been explored. In a search for compounds that
would work synergistically with spectinomycin (SPT), a high-
throughput synergy screen (HTSS) was performed with a library
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of molecules with known pharmacological properties. Three
structural cores were found to enhance the antibiotic activity
of SPT: the macrolides, azoles, and butyrophenones (Ramon-
Garcia et al., 2011). Bromperidol displayed bactericidal activity,
was effective against Mtb in a macrophage model, and displayed
similar enhancement of the activities of RIF, STR, clofazimine,
and clarithromycin. In addition to its anti-TB activity, TMC207
has also been shown to speed up treatment with the first-line anti-
TB drugs (Diacon et al., 2009). Lechartier et al. combined BTZ043
with known and experimental TB treatments (Lechartier et al.,
2012). In most cases additive interactions of BTZ043 with the sec-
ond TB treatment were observed. However, BTZ043 was shown to
act synergistically with TMC207. Both drugs used at one-quarter
of the MIC concentration showed more significant growth retar-
dation than TMC207 at its MIC value alone. The authors suggest
that BTZ043 inhibits DprE1 leading to weaker cell walls allowing
transmission of TMC207 across the cell membrane. In a recent
study, SQ109 acted synergistically with RIF and TMC207 (Reddy
et al., 2010).
Inhibition of resistance enzymes
The use of inhibitors of drug-modifying enzymes along with
currently approved anti-TB drugs complements the drug com-
bination strategy described above. Perhaps the best-known com-
bination of this type is a β-lactam and a β-lactamase inhibitor.
A combination of clavulanate and meropenem proved to be
active against both susceptible and XDR-Mtb strains (Hugonnet
et al., 2009) A novel β-lactamase inhibitor, NXL104, was recently
reported and found to bind BlaC in a 1:1 molar ratio (Xu et al.,
2012). Recently, inhibitors of the AG-resistance enzyme Eis were
discovered (Green et al., 2012). These compounds encompass
a wide variety of chemical structures and offer a plethora of
scaffolds to be studied for development of novel anti-TB drug
adjuvants. While these compounds have not yet been tested in
AG-resistantMtb strains, combinations of inhibitors with AGs are
predicted to restore the antibacterial activity of AGs in cells.
CONCLUSION
Even though current TB treatments are still broadly employed,
the rapid spread of MDR-TB and XDR-TB is a rising threat.
Based on our current understanding of the resistance mecha-
nisms, contemporary strategies are focused on generating com-
pounds that will avoid or overcome the defenses of Mtb. Research
is being carried out to find novel compounds that will dis-
rupt DNA, cell membrane biosynthesis, and general cellular
metabolism. Other lines of inquiry are focusing on pathways cur-
rently not used to treat TB: cellular energetics, cellular transport,
and other aspects of cellular metabolism. A third facet relies on
current TB treatment and combines drugs to achieve synergis-
tic effects, either blocking two separate pathways or inhibiting
a drug-modifying enzyme. While many of the compounds dis-
cussed herein are far from being approved as drugs, the recent
approval of TMC207 and the multitude of efforts in searching
for novel antibiotics give hope for the discovery of novel TB
treatments.
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